A Phase 1B/2A, Open-label, Non-randomized, Multi-arm Study of TL32711 in Combination With Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors.

Trial Profile

A Phase 1B/2A, Open-label, Non-randomized, Multi-arm Study of TL32711 in Combination With Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 02 Jun 2016

At a glance

  • Drugs Birinapant (Primary) ; Carboplatin; Docetaxel; Doxorubicin liposomal; Gemcitabine; Irinotecan; Paclitaxel
  • Indications Solid tumours
  • Focus Adverse reactions; Biomarker; Pharmacogenomic
  • Most Recent Events

    • 07 May 2014 According to the ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
    • 12 Jun 2013 Planned end date changed from 1 Dec 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.
    • 02 Jun 2013 Phase I results in 124 patients presented at ASCO 2103, according to a TetraLogic Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top